• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

对潜在病因进行最佳治疗是慢性呼吸道疾病最有效的抗菌药物管理：从囊性纤维化中吸取的教训。

Optimal treatment of the underlying aetiology is the most effective antimicrobial stewardship for chronic respiratory disease: a lesson learned from cystic fibrosis.

作者信息

Rademacher Jessica, Martin Luise, Theloe Anja, Stahl Mirjam, Mall Marcus A, Joean Oana, Fuge Jan, Hansen Gesine, Welte Tobias, Schütz Katharina, Ringshausen Felix C, Dittrich Anna M

机构信息

Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany.

Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover, Germany.

出版信息

ERJ Open Res. 2023 Aug 29;9(4). doi: 10.1183/23120541.00356-2023. eCollection 2023 Jul.

DOI:10.1183/23120541.00356-2023
PMID:37650087
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10463032/
Abstract

https://bit.ly/3ptrmV8.

摘要

https://bit.ly/3ptrmV8. （链接无法直接翻译，保留原文）

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1696/10463032/a0b37a61823b/00356-2023.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1696/10463032/a0b37a61823b/00356-2023.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1696/10463032/a0b37a61823b/00356-2023.01.jpg

相似文献

1
Optimal treatment of the underlying aetiology is the most effective antimicrobial stewardship for chronic respiratory disease: a lesson learned from cystic fibrosis.对潜在病因进行最佳治疗是慢性呼吸道疾病最有效的抗菌药物管理：从囊性纤维化中吸取的教训。
ERJ Open Res. 2023 Aug 29;9(4). doi: 10.1183/23120541.00356-2023. eCollection 2023 Jul.
2
Antimicrobial Stewardship in Cystic Fibrosis.囊性纤维化中的抗菌药物管理。
J Pediatric Infect Dis Soc. 2022 Sep 7;11(Supplement_2):S53-S61. doi: 10.1093/jpids/piac071.
3
Finding the relevance of antimicrobial stewardship for cystic fibrosis.寻找抗菌药物管理策略与囊性纤维化的相关性。
J Cyst Fibros. 2020 Jul;19(4):511-520. doi: 10.1016/j.jcf.2020.02.012. Epub 2020 Feb 29.
4
[Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].[中国专家共识声明：囊性纤维化的诊断与治疗（2023年）]
Zhonghua Jie He He Hu Xi Za Zhi. 2023 Apr 12;46(4):352-372. doi: 10.3760/cma.j.cn112147-20221214-00971.
5
Current state of antimicrobial stewardship and organ transplantation in Thailand.泰国抗菌药物管理和器官移植的现状。
Transpl Infect Dis. 2022 Oct;24(5):e13877. doi: 10.1111/tid.13877.
6
Is there a role for antimicrobial stewardship in cystic fibrosis?抗菌药物管理在囊性纤维化中是否有作用？
Ann Am Thorac Soc. 2014 Sep;11(7):1116-9. doi: 10.1513/AnnalsATS.201401-034OI.
7
How do hospital respiratory clinicians perceive antimicrobial stewardship (AMS)? A qualitative study highlighting barriers to AMS in respiratory medicine.医院呼吸科临床医生如何看待抗菌药物管理（AMS）？一项定性研究揭示了呼吸医学中抗菌药物管理的障碍。
J Hosp Infect. 2017 Aug;96(4):316-322. doi: 10.1016/j.jhin.2017.05.001. Epub 2017 May 5.
8
Antimicrobial stewardship in wound care implementation and measuring outcomes: results of an e-survey.伤口护理中抗菌药物管理的实施和效果评估：电子调查结果。
J Wound Care. 2022 Jan 2;31(1):32-39. doi: 10.12968/jowc.2022.31.1.32.
9
Influences on nurses' engagement in antimicrobial stewardship behaviours: a multi-country survey using the Theoretical Domains Framework.影响护士参与抗菌药物管理行为的因素：采用理论领域框架的多国调查。
J Hosp Infect. 2022 Nov;129:171-180. doi: 10.1016/j.jhin.2022.07.010. Epub 2022 Jul 16.
10
Antimicrobial stewardship in the Western Cape: A situational analysis of existing facility-level initiatives.西开普省的抗菌药物管理：现有机构层面举措的情况分析。
S Afr Med J. 2021 Apr 30;111(5):421-425. doi: 10.7196/SAMJ.2021.v111i5.14645.

本文引用的文献

1
Elexacaftor - Tezacaftor - Ivacaftor treatment improves systemic infection parameters and colonization rate in patients with cystic fibrosis a monocentric observational study.依列卡福妥-替扎卡福妥-依伐卡托治疗可改善囊性纤维化患者的全身感染参数和定植率：一项单中心观察性研究
Heliyon. 2023 Apr 24;9(5):e15756. doi: 10.1016/j.heliyon.2023.e15756. eCollection 2023 May.
2
Using an Antibiogram Profile to Improve Infection Control and Rational Antimicrobial Therapy in an Urban Hospital in The Gambia, Strategies and Lessons for Low- and Middle-Income Countries.利用抗菌谱改善冈比亚一家城市医院的感染控制和合理抗菌治疗，低收入和中等收入国家的策略与经验教训。
Antibiotics (Basel). 2023 Apr 21;12(4):790. doi: 10.3390/antibiotics12040790.
3
Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist.
药物改善 CFTR 功能可迅速降低痰中病原体密度，但肺部感染通常持续存在。
J Clin Invest. 2023 May 15;133(10):e167957. doi: 10.1172/JCI167957.
4
Impact of elexacaftor/tezacaftor/ivacaftor on bacterial cultures from people with cystic fibrosis.依列卡福妥/替扎卡福妥/依伐卡托对囊性纤维化患者细菌培养的影响
Pediatr Pulmonol. 2023 May;58(5):1569-1573. doi: 10.1002/ppul.26362. Epub 2023 Mar 1.
5
New concepts in antimicrobial resistance in cystic fibrosis respiratory infections.囊性纤维化呼吸道感染中的抗菌药物耐药新概念。
J Cyst Fibros. 2022 Nov;21(6):937-945. doi: 10.1016/j.jcf.2022.10.005. Epub 2022 Oct 18.
6
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study.依伐卡托钠/泰比卡托钠/埃他卡托钠在 和最小功能突变杂合子且年龄在 6 至 11 岁的囊性纤维化儿童中的疗效和安全性：一项 3b 期、随机、安慰剂对照研究。
Am J Respir Crit Care Med. 2022 Dec 1;206(11):1361-1369. doi: 10.1164/rccm.202202-0392OC.
7
The Rapid Reduction of Infection-Related Visits and Antibiotic Use Among People With Cystic Fibrosis After Starting Elexacaftor-Tezacaftor-Ivacaftor.依伐卡托与泰他卡托和艾乐卡托联合治疗后囊性纤维化患者感染相关就诊和抗生素使用的快速减少。
Clin Infect Dis. 2022 Sep 30;75(7):1115-1122. doi: 10.1093/cid/ciac117.
8
Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two Alleles.依伐卡托/泰它卡托/艾氟康唑治疗对具有一个或两个等位基因的囊性纤维化患者 CFTR 功能的影响。
Am J Respir Crit Care Med. 2022 Mar 1;205(5):540-549. doi: 10.1164/rccm.202110-2249OC.
9
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.依伐卡托/泰它卡托/艾氟卡托治疗囊性纤维化的临床疗效：一项临床试验。
Am J Respir Crit Care Med. 2022 Mar 1;205(5):529-539. doi: 10.1164/rccm.202108-1986OC.
10
PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy.承诺：与 CF 社区合作，了解接受高效 CFTR 调节剂治疗的患者的新兴临床和研究需求。
J Cyst Fibros. 2021 Mar;20(2):205-212. doi: 10.1016/j.jcf.2021.02.003. Epub 2021 Feb 19.